Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 20/20 | 0.57 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.54 |
| ▸ | OXTR | P30559 | 7/20 | 0.54 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.54 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5674309 | 0.93 | AVPR1B (0.62) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL7462034 | 0.91 | AVPR1B (0.48) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL7472009 | 0.91 | AVPR1B (0.48) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL7471705 | 0.90 | AVPR1B (0.56) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5674084 | 0.89 | AVPR1B (0.55) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL7471393 | 0.89 | AVPR1B (0.49) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5677857 | 0.88 | AVPR1B (0.56) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5678952 | 0.88 | AVPR1B (0.45) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL7473969 | 0.87 | AVPR1B (0.46) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5677741 | 0.87 | AVPR1B (0.56) | AVPR1BAVPR1AOXTRAVPR2GPR65 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119086-B2 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2006-10-10 | — | — | US | disclosed |
| EP-1419150-B1 | PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2005-04-27 | — | — | EP | disclosed |
| US-20040180878-A1 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | US | disclosed |
| EP-0687251-B1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI SYNTHELABO (FR) | 2002-02-27 | — | — | EP | disclosed |
| US-5773612-A | VASOPRESSIN OR OXYTOCIN RECEPTORS | SANOFI (FR) | 1998-06-30 | — | — | US | disclosed |
| US-5594023-A | 1,3-dihydroindol-2-one derivatives substituted in the 3-position by a nitrogen-containing group, their preparation and the pharmaceutical compositions in which they are present | SANOFI (FR) | 1997-01-14 | — | — | US | disclosed |
| WO-1995018105-A1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI (FR) | 1995-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180878-A1 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | AVPR2, AVPR1A, AVPR1B | AVPR1B 3/4885AVPR1A 2/4885OXTR 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.